OBJECTIVE To acquire the real-world incidence of ceftazidime-avibactam sodium (CAZ)-related adverse reactions of blood system among a large sample of drug medication patients based on the active monitoring system so as to provide reference for safe clinical use of drugs.

METHOD With the help of ′Adverse Drug Event Active Surveillance and Assessment System-Ⅱ′ (ADE-ASAS-Ⅱ), the use of CAZ of the patients who were hospitalized in Chinese PLA General Hospital from Jan. 1, 2020 to Dec. 31, 2023 were retrospectively and automatically monitored, the patients who were alarmed by system were evaluated by two persons, the incidence rates of CAZ-related thrombocytopenia, hemoglobin decreased and leucopenia were calculated, and the related influencing factors were analyzed.

RESULTS Among the 278 case-times (191 cases) of patients who were treated with drugs and were enrolled in the study, there were 3 (1.08%) case-times of thrombocytopenia, 8 (2.88%) case-times of hemoglobin decreased and 19 (6.83%) case-times of leucopenia; the total incidence of adverse reactions of blood system was 10.79%. Logistic regression analysis showed that age and duration of drug administration were the influencing factors for the CAZ-related adverse reactions of blood system.

CONCLUSIONS It is common for the CAZ-related adverse reactions of blood system. The middle-aged and elderly patients who take drug therapy for a long time period are more likely to have the blood system-related adverse reactions. It is necessary to focus on the monitoring of renal function of the patients and adjust the dosage of administration in a timely manner so as to reduce the incidence of adverse reactions of the blood system.